Communiqués Syros Pharmaceuticals, Inc.

Actions

SYRS

US87184Q2066

Temps réel estimé Cboe BZX Autres places de cotation 15:54:54 16/07/2024			Varia. 5j.	Varia. 1 janv.
6,415 ^USD	+4,48 %		+12,82 %	-19,77 %

25/06	Transcript : Syros Pharmaceuticals, Inc. - Special Call
05/06	Transcript : Syros Pharmaceuticals, Inc. - Shareholder/Analyst Call

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression	13/06	BU
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update	14/05	BU
Syros to Participate in Upcoming Investor Conferences	07/05	BU
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024	07/05	BU
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09/04	BU
Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03/04	AQ
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04	BU
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	27/03	BU
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial	25/03	BU
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024	20/03	BU
Syros to Participate in TD Cowen 44th Annual Health Care Conference	27/02	BU
Thinking about buying stock in Applied UV, Crowdstrike, Syros Pharmaceuticals, Captivision, or Polestar Automotive?	01/02	PR
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene	08/01	BU
Thinking about buying stock in NGM Biopharmaceuticals, Syros Pharmaceuticals, Mereo BioPharma, BTCS Inc, or Sentage Holdings?	02/01	PR
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants	19/12	BU
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine	06/12	BU
Syros to Participate in Upcoming Investor Conferences	21/11	BU
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update	14/11	BU
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023	07/11	BU
Syros Pharmaceuticals : Costs Associated with Exit/Disposal - Form 8-K	02/10/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Syros Pharmaceuticals, Inc.

Actions

SYRS

US87184Q2066

Communiqués

Filtres